despit deep devic impact reason optim
test leadership sign spring stabil
abbott report met investor enthusiasm
compani beat forecast top consensu expect
manag suspend guidanc gave felt upbeat
commentari sign stabil declin devic procedur volum
potenti v-like gradual recoveri back half year nod toward
consensu plan continu invest busi overal tone seem
confid impact devic segment deeper model
wors estim base smaller player result
 impact like start week earlier project segment
particularli electrophysiolog neuromodul structur heart see
steeper declin rang expect like commentari point
sign stabil believ prior trajectori eventu improv
start june remain reason beyond devic diagnost big focu
continu fast mover develop launch test
mass screen key requir reopen economi abt leadership
like leav room upsid diagnost sale forecast abt overal
busi like remain shelter compani posit solid recoveri
believ current multipl alreadi reflect reiter neutral rate
despit devic pain beat forecast ou devic segment
diabet bright spot especi ou revenu beat even pre-
coronaviru forecast januari underestim declin seen
procedur volum quarter particularli vascular structur heart
depend devic sub-seg previous forecast
declin procedur volum last two week march review
result estim drop-off start week earlier anticip
end march segment may experienc declin
vs normal procedur volum think elect categori like structur
heart electrophysiolog neuromod impact
diagnost result hurt lower routin test still beat
forecast segment includ lab follow week
launch igg serolog test learn igm serolog test work
previous increas estim much diagnost segment
add increas back half year coronavirus-rel test
like becom regular occurr forese futur keep
forecast conserv better understand benefit possibl
establish pharmaceut nutrit busi robust
sinc demand product larg consumer-driven nutrit experienc
bolu benefit period consum rush stock product
particularli pediatr categori expect reoccur
gross margin rel healthi despit hit high-margin
busi like devic diagnost part anticip
major cost-cut expect maintain normal level oper spend
throughout crisi
valuat maintain neutral rate risk discuss
factset btig estim compani
document million except per share amount
abbott rate neutral recent year abbott share outperform peer overal market benefit
solid pipelin launch high-growth area diabet structur heart diagnost remain posit
base busi see pathway toward drive high-single-digit revenu growth although mitraclip still modest portion
busi still earli stage penetr suggest signific runway ahead said share trade mid-
teen premium comp group feel share rel valuat appropri reflect risk vs reward
updat disrupt
reimburs approv coverag decis
pandem resolv mid-summ gradual recoveri follow
stabl procedur growth price
rapid resolut pandem faster recoveri afterward
expans current tam
pandem last longer slower littl recoveri afterward
cut reimburs
abbott one largest diversifi
nutrit diagnost medic
report revenu consensu estim organ sale growth particular benefit
beat vs forecast establish pharma major beat nutrit due part pre-pandem stockpil
devic result forecast overestim fx impact impact declin procedur volum ou hand
underestim impact sale total world-wide devic segment revenu consolid sale
came consensu vs consensu sale materi wors expect miss
estim hf structur heart segment diabet care stood especi durabl
segment trounc estim estim
segment diagnost slightli exceed street estim vs oper sale growth led
incred growth molecular test y/i lastli oper nutrit sale growth outstrip model
growth meaning out-perform especi pediatr nutrit beat estim
profit metric report result close line predict gross margin bp forecast
sg spend slightli lower model expens even higher overal
ebit margin exceed model line lower interest expens lower model
partial off-set higher tax expens higher model boost adjust ep share nickel higher
forecast
whole factor revenu beat dont make major chang total revenu remaind
year howev meaning reduc devic revenu project offset increas pocket
diagnost busi slight increas devic sale reflect less impact anticip
quarterli basi total revenu estim decreas off-set increas total revenu
outsid devic essenti increas diagnost back half year alreadi incorpor increas
dont make meaning chang epd nutrit forecast assum benefit seen nutrit quarter
due consum stock ahead pandem like repeat
 slightli lower gross margin increas oper spend percentag revenu reflect reduc
revenu estim forecast revenu adj ep lp full year
project revenu adj ep ep
abbott rate neutral recent year abbott share outperform peer overal market benefit
solid pipelin launch high-growth area diabet structur heart diagnost remain posit
base busi see pathway toward drive high-single-digit revenu growth although mitraclip modest portion
busi still earli stage penetr suggest signific runway ahead said share trade
premium comp group feel share rel valuat appropri reflect risk vs reward risk rate
includ disrupt multipl expans competit healthcar polici chang healthcar fall favor fda
regulatori agenc litig product delay
btig cover compani mention report
appendix analyst certif import disclosur
